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Abstract
Introduction Aberrant pre-mRNA splicing can be more
detrimental to the function of a gene than changes in the length
or nature of the encoded amino acid sequence. Although
predicting the effects of changes in consensus 5' and 3' splice
sites near intron:exon boundaries is relatively straightforward,
predicting the possible effects of changes in exonic splicing
enhancers (ESEs) remains a challenge.
Methods As an initial step toward determining which ESEs
predicted by the web-based tool ESEfinder in the breast cancer
susceptibility gene BRCA1 are likely to be functional, we have
determined their evolutionary conservation and compared their
location with known BRCA1 sequence variants.
Results Using the default settings of ESEfinder, we initially
detected 669 potential ESEs in the coding region of the
BRCA1 gene. Increasing the threshold score reduced the total
number to 464, while taking into consideration the proximity to
splice donor and acceptor sites reduced the number to 211.
Approximately 11% of these ESEs (23/211) either are identical
at the nucleotide level in human, primates, mouse, cow, dog and
opossum Brca1 (conserved) or are detectable by ESEfinder in
the same position in the Brca1  sequence (shared). The
frequency of conserved and shared predicted ESEs between
human and mouse is higher in BRCA1  exons (2.8 per 100
nucleotides) than in introns (0.6 per 100 nucleotides). Of
conserved or shared putative ESEs, 61% (14/23) were
predicted to be affected by sequence variants reported in the
Breast Cancer Information Core database. Applying the filters
described above increased the colocalization of predicted ESEs
with missense changes, in-frame deletions and unclassified
variants predicted to be deleterious to protein function, whereas
they decreased the colocalization with known polymorphisms or
unclassified variants predicted to be neutral.
Conclusion In this report we show that evolutionary
conservation analysis may be used to improve the specificity of
an ESE prediction tool. This is the first report on the prediction
of the frequency and distribution of ESEs in the BRCA1 gene,
and it is the first reported attempt to predict which ESEs are
most likely to be functional and therefore which sequence
variants in ESEs are most likely to be pathogenic.
Introduction
Studies of the pathogenicity of nucleotide sequence variants
in disease-associated genes usually focus on the effect on
encoded protein structure and function. However, the delete-
rious effects of such changes may also be attributed to regu-
latory defects such as altered transcript stability [1] and
abnormal transcript splicing [2-4].
Splicing is the process of removing introns from pre-mRNA
transcripts. Splicing signals include a number of sequence
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elements in the precursor mRNA, including splice site (donor
and acceptor) consensus sequences and a branch point
sequence (for review, see Cartegni and coworkers [5]). Splic-
ing is mediated by the spliceosome – a complex of small
nuclear RNAs and associated proteins that recognizes splic-
ing signals and catalyzes intron removal. The splice site con-
sensus sequences and the sequences of small nuclear RNAs
are highly conserved through evolution (for reviews, see Hast-
ings and Krainer [6] and Black [7]). Disease-associated muta-
tions in splicing consensus sequences have been identified in
several genes. In BRCA1, for example, the IVS10-2A->C
mutation [8] and the IVS20+1G>A mutation [9] are strongly
associated with breast cancer predisposition.
Splicing is also regulated by exonic splicing silencers and
exonic splicing enhancers (ESEs). ESEs, and the arginine/ser-
ine-rich family of proteins (SR proteins) that bind to these
sequences (for review, see Cartegni and coworkers [5]) are
conserved across vertebrates [10]. Recently, bioinformatic
sequence analysis tools (ESEfinder and Rescue-ESE) that
predict the presence of ESEs became available, and these
may facilitate prediction of the effect of sequence variants on
transcript splicing [10,11]. Mutations that lead to alterations in
ESE motifs can result in failure of SR proteins to recognize and
bind to the ESE motif, which in turn leads to failure of the spli-
ceosome machinery to recognize the exon, resulting in exon
skipping. A single nucleotide mutation in exon 18 of BRCA1
(G5199T), for example, has been shown to disrupt an ESE
motif recognized by SF2/ASF, leading to exon skipping [2].
Single exonic nucleotide sequence variations resulting in
altered mRNA transcript splicing have also been reported as
contributing to other diseases, for example spinal muscular
atrophy [12,13].
The BRCA1 gene is implicated in both familial and sporadic
breast cancers. BRCA1 encodes a 1863 amino acid nuclear
phosphoprotein with tumor suppressor activity, with functions
that include the regulation of DNA damage repair, transcrip-
tion, cell cycle arrest and apoptosis (for review, see Venkitara-
man [14]). Loss of BRCA1  function is likely to result in
genomic instability through a combination of loss of cell cycle
checkpoint control post-DNA damage, loss of efficient DNA
damage repair, and loss or limited initiation of apoptosis path-
ways. Loss of BRCA1 function can arise due to mutation and
by aberrant regulation at the transcriptional and post-transcrip-
tional levels [15,16].
Over a thousand BRCA1 single nucleotide sequence varia-
tions have been reported in the Breast Cancer Information
Core (BIC) database [17]. Given that BRCA1  sequencing
(and thus variant identification) is generally undertaken in indi-
viduals with cancer or with a family history of cancer, it is
assumed that the majority of these variants were identified in
such individuals, and that at least a fraction of them predis-
pose to cancer. The pathogenicity of only a small number of
variants has been tested functionally or inferred genetically. It
is likely that a proportion of these sequence variants, including
some missense mutations and apparent truncation variants
such as G5199T [2], may exert a pathogenic effect by disrupt-
ing ESE motifs and altering BRCA1 splicing.
At least 30 alternatively spliced isoforms of BRCA1 have been
identified, but only a small proportion of these – including the
full length, ∆9–10, ∆11q and ∆9–10,11q isoforms – have
been shown to be expressed in a wide variety of cell and tissue
types (for review, see Orban and Olah [18]). A recently identi-
fied protein produced from the BRCA1 locus is BRCA1-IRIS,
which arises via abnormal BRCA1 splicing [19]. The precise
mechanisms that underlie the generation of normal and abnor-
mal BRCA1 splice variants, and in particular the role of ESEs
and SR proteins, are not well understood.
We set out to predict functional ESEs in BRCA1 using a mul-
tifaceted bioinformatics approach. The ESEfinder program
was used to predict ESEs located proximally to the ends of
exons in the human BRCA1 gene. The evolutionary conserva-
tion of these ESEs was then examined among primate, mouse,
cow, dog and opossum Brca1  sequences. Reported
sequence variations in BRCA1 were compared with predicted
ESEs, as a means of identifying sequence changes that may
exert pathogenic effects through altering the splicing of
BRCA1 transcripts.
Materials and methods
Predicting exonic splice enhancers
The web-based ESEfinder 2.0 program [11,20] searches for
sequences that act as binding sites for four members of the
serine/arginine rich family of splicing enhancer proteins. Input
sequences are screened for consensus binding sequences for
the SR proteins SF2/ASF, SC35, SRp40 and SRp55, devel-
oped using the SELEX (systematic evolution of ligands by
exponential enrichment) procedure [11,21,22]. The program
scores the input sequences according to fit with the loose
consensus sequences; scores above a default threshold value
are predicted to act as SR protein binding sites and thus func-
tion as ESEs. Increased threshold values of 2.0 for SF2/ASF
(from 1.956) and 3.0 for SC35 (from 2.383), SRp40 (from
2.670) and SRp55 (from 2.676) were used in order to mini-
mize false-positive results [23]. The wild-type BRCA1 cDNA
sequence (GenBank:U14680) was used as input in an exon-
by-exon manner. The BRCA1  open reading frame (ORF)
begins 19 nucleotides into exon 2 and continues 125 nucle-
otides into exon 24. The alternative first exons 1a and 1b were
not analyzed because it was assumed that the inclusion of
these exclusive exons was driven by promoter use and not
splicing factors. BRCA1 sequences for introns 5, 6, 9 and 10
(GenBank:L78833) were also screened in their entirety using
ESEfinder under the same conditions.Available online http://breast-cancer-research.com/content/7/6/R929
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Cross-species sequence analysis
The Brca1 cDNA sequences for a selection of four primate
organisms ('the primates': chimpanzee [Pan troglodytes, Gen-
Bank:AY365046], orang-utan [Pongo pygmaeus, Gen-
Bank:AY589040], rhesus monkey [Macaca mulatto,
GenBank:AY589041] and gorilla [Gorilla gorilla, Gen-
Bank:AY589042]), mouse (Mus musculus, Gen-
Bank:NM_009764), Cow (Bos Taurus,
GenBank:NM_178573), opossum (Monodelphis domestica,
GenBank:AY994160) and dog (Canis familiaris, Gen-
bank:NM_001013416) were obtained from the National
Center for Biotechnology Information [24]. Splice junctions
were predicted by aligning sequences to the human BRCA1
exon sequences. The Brca1  cDNA sequences were then
screened using ESEfinder 2.0 in an exon-by-exon manner
using the same threshold scores as were used for the human
sequence. Nucleotide sequence alignments were performed
using a clustal alignment program, with gaps between
sequences noted and accounted for when determining posi-
tion of predicted ESEs within exons. Mouse Brca1 sequences
for introns 5, 6, 9 and 10 (chr11:101160890-101222966)
were obtained from the University of California Santa Cruz
Genome Bioinformatics project [25].
Previously reported BRCA1 sequence variants
The online BIC database [17] contains detailed information on
sequence variants in BRCA1. The BIC database was used as
resource for a range of mutation types analyzed, including mis-
sense (n = 17), nonsense (n = 167), splicing (n = 5), insertion
or deletion mutations that maintained the ORF (n  = 19),
unclassified variant (UV; n = 387) and polymorphisms (n =
12). Mutations were examined only if they were located within
an exon. Each variant cDNA sequence was then screened
using ESEfinder 2.0 in an exon-by-exon, variant-by-variant
manner, and the results were compared with those for wild-
type sequence to identify any loss, gain, or alteration in pre-
dicted SR protein binding sites.
For the colocalization analysis, additional single nucleotide
polymorphisms (SNPs) were obtained from the SNPper Gene
Finder online database [26] (BRCA1 SNP data set SS965).
Only exonic SNPs were analyzed, and those also reported in
the BIC database were not included. In total, 21 SNPs from
SNPper and 12 from BIC were used in this analysis.
Amino acid substitution analysis
An alignment of 12 full-length BRCA1 protein sequences was
made using the multiple sequence alignment program
3DCoffee [27], which also incorporates alignment to X-ray
and nuclear magnetic resonance (NMR) structures. The pro-
gram was run using Mlalign_id_pair, Mslow_pair and
Mclustalw_aln to generate amino acid alignments, and
Mfugue_pair to generate structure sequence alignments. Gen-
Bank accession numbers for BRCA1 protein sequences used
in the alignment were as follows: human (Homo sapiens),
NP_009225; chimpanzee (Pan troglodytes), AAG43492;
gorilla (Gorilla gorilla), AAT44835; orang-utan (Pongo pyg-
maeus), AAT44834; rhesus macaque (Macaca mulatta),
AAT44833; mouse (Mus musculus), AAD00168; dog (Canis
familiaris), AAC48663; cow (Bos taurus), NP_848668; gray,
short-tailed opossum (Monodelphis domestica), AY994160;
chicken (Gallus gallus), NP_989500; African clawed frog
(Xenopus laevis), AAL13037; and green-spotted pufferfish
(Tetraodon nigroviridis), AAR89523. For the structure compo-
nent of the alignment, we used BRCA1 RING NMR structure
1JM7.pdb and the BRCA1 BRCT repeat crystal structures
1JNX.pdb and 1T29.pdb [28-30].
BRCA1 missense substitutions were analyzed against the
alignment using two programs, namely SIFT and A-GVGD
[31,32]. The joint analysis was used to define a group of sub-
stitutions that should be highly enriched for deleterious muta-
tions and a group that should be highly enriched for neutral
substitutions. The enriched deleterious group consisted of
those substitutions that had SIFT scores ≤0.05 and A-GVGD
scores of GV<62 and GD>0. The enriched neutral group con-
sisted of those substitutions that had SIFT scores >0.1 and A-
GVGD scores of GV>0 and GD = 0.
Rescue-ESE
A limited analysis of BRCA1  (exons 2–10) was also per-
formed using the recently described ESE detection program
Rescue-ESE [10,33] using the web-based facility [34].
Human  BRCA1  was analyzed using the human algorithm
whereas mouse Brca1  was analyzed using the mouse
algorithm.
Statistical analyses
Differences in the frequency of ESEs in exons and introns, and
in the colocalizations of ESEs with reported sequence
changes were assessed using the Pearson χ2 test. When
expected cell numbers were smaller than five, the Fisher's
exact test rather than Pearson χ2 test was used to obtain an
estimate of significance.
Results
BRCA1 exons contain numerous putative exonic splice 
enhancer sequences
ESEfinder initially predicted 669 ESEs in the 5592 nucleotide
BRCA1 ORF. In order to reduce the number of potential false
positives, increased threshold scores were used, in accord-
ance with the approach used to study ESEs in TP53 [23].
After increasing the threshold score to 2.0 for SF2/ASF and
3.0 for SC35, SRp40 and SRp55, ESEfinder predicted 464
ESEs in BRCA1  (Table 1). The majority of these potential
ESEs are predicted to bind SRp40 and SF2/ASF (162 and
145 ESEs, respectively), whereas smaller numbers are pre-
dicted for SC35 and SRp55 (92 and 65, respectively).Breast Cancer Research    Vol 7 No 6    Pettigrew et al.
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BRCA1  exon 11 comprises over 60% of the coding
sequence, and 57% (265/464) of ESEfinder predicted ESEs
were located in the exon. Although some regulatory elements
can be located several kilobases away [35], studies of the
molecular mechanisms of splicing suggest that ESEs occupy
specific positions relative to the 5' and 3' ends of exons
[13,36]. Thus, it is less likely that predicted ESEs in the centre
of BRCA1 exon 11 are functional. We therefore employed an
exon 'cutoff' for our analysis that limits the amount of exon
sequence analyzed to the first and last 125 nucleotides of an
exon. The introduction of the nucleotide limit affects only exons
11 (3.4 kilobases in length) and exon 16 (311 nucleotides in
length), and reduces the total number of predicted ESEs to
211.
Approximately 11% of predicted BRCA1 exonic splice 
enhancers are evolutionarily conserved
The molecular mechanisms that underlie the major splicing
processes are highly conserved through evolution (reviews
available elsewhere [5,7,37]). Given this and the high nucle-
otide sequence conservation of ESEs [10] and amino acid
homology of the SR proteins that bind ESEs (e.g. see Hana-
mura and coworkers [38]), it is reasonable to suggest that
those ESEs that are also found in Brca1 sequences from other
species are more likely to be functional. The BRCA1 mRNA
sequences from human, four primates as well as mouse, cow,
dog and opossum were analyzed. Gaps in sequence align-
ments were accounted for, and ESEfinder 2.0 outputs were
compared with that for the human sequence. Output was then
Table 1
Putative ESEs in BRCA1
Exon Length (nt) Predicted 
SF2/ASF 
ESEs
Predicted 
SC35 
ESEs
Predicted 
SRp40 
ESEs
Predicted 
SRp55 
ESEs
Total 
predicted 
ESEs
Nucleotides 
mapping to 
predicted 
ESEs
ESEs as % of 
exon
28 0 001121 3 1 6 . 2 5 0
35 4 002131 8 3 3 . 3 3 3
57 8 204284 1 5 2 . 5 6 4
68 9 103042 2 2 4 . 7 1 9
71 4 0 23431 2 5 7 4 0 . 7 1 4
81 0 6 43311 1 5 1 4 8 . 1 1 3
94 6 100017 1 5 . 2 1 7
1 0 7 7 213062 8 3 6 . 3 6 4
11 3426 (250) 90 (7) 48 (4) 93 (7) 34 (2) 265 (20) 1405 (106) 41.010 (42.400)
1 2 8 9 312284 4 4 9 . 4 3 8
1 3 1 7 2 43431 4 8 0 4 6 . 5 1 2
1 4 1 2 7 42721 5 6 6 5 1 . 9 6 9
1 5 1 9 1 72631 8 1 0 5 5 4 . 9 7 4
16 311 (250) 5 (4) 9 (6) 10 (8) 3 (1) 27 (19) 143 (110) 45.981 (44.000)
1 7 8 8 34221 1 4 9 5 5 . 6 8 2
1 8 7 8 311163 2 4 1 . 0 2 6
1 9 4 1 000000 0 . 0 0 0
2 0 8 4 24401 0 3 8 4 5 . 2 3 8
2 1 5 5 112042 3 4 1 . 8 1 8
2 2 7 4 212384 0 5 4 . 0 5 4
2 3 6 1 332193 7 6 0 . 6 5 6
2 4 1 2 5 66732 2 8 9 7 1 . 2 0 0
Total 5592 (2355) 145 (61) 92 (45) 162 (74) 65 (31) 464 (211) 2388 (1056) 42.704 (44.841)
Numbers in parentheses refer to those sequences within 125 nucleotides (nt) of the exon end. ESE, exonic splicing enhancer.Available online http://breast-cancer-research.com/content/7/6/R929
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divided in two: 'conserved ESEs', referring to those predicted
ESEs that were identical in sequence and exon position
across all species examined; and 'shared ESEs', referring to
those sequences for which ESEfinder predicted a binding site
for the same SR protein to the same exon position, although
the nucleotide sequence of the motif was not identical across
species (Fig. 1). In approximately 2% (5/211) of predictions,
identical ESE consensus sequences predicted in the human
BRCA1 sequence were also found in all Brca1 sequences
examined. In a further 9% (18/211) of cases the same ESE
was predicted in the same position of human BRCA1 and
other  Brca1  sequences, albeit with a different nucleotide
sequence. Together, these findings suggest that approxi-
mately 11% (23/211) of ESEs are likely to be present in
human  BRCA1, primate, mouse, cow, dog and opossum
Brca1 genes.
Conserved exonic splice enhancers are more frequent in 
BRCA1 exons than introns
The frequency of predicted ESE motifs in exons averages
11.96 ESEs per 100 nucleotides for complete exonic
sequence, which is greater than the number of predicted
ESEs in a random sample of BRCA1 intronic DNA (introns 5,
6, 9 and 10), which occur at a rate of 10.90 per 100 nucle-
otides. Given that SR proteins primarily bind to sequences in
exonic DNA [5], this suggests that there is potentially a high
level of false positives associated with ESEfinder.
Applying the increased threshold decreased the frequency of
predicted ESEs in both exons (8.30 predicted ESEs per 100
nucleotides) and introns (7.66 predicted ESEs per 100 nucle-
otides), with no significant difference. However, applying the
125 nucleotide cutoff changed the frequency in exons to 8.96
predicted ESEs per 100 nucleotides and in introns to 5.6 pre-
dicted ESEs per 100 nucleotides (P = 0.001). This suggests
Figure 1
Shared and conserved predicted ESEs in the human and mouse BRCA1 genes Shared and conserved predicted ESEs in the human and mouse BRCA1 genes. The BRCA1 open reading frame (ORF) divided into exons is shown 
to scale, with shorter analyzed fragments of exons 11 and 16. Conserved exonic splicing enhancers (ESEs) are shown on the top of the ORF, with 
shared ESEs shown on the bottom. Overlapping ESE motifs are staggered. SF2/ASF ESE motifs are shown in red, with SC35 in blue, SRp40 in 
green and SRp55 in yellow, also to scale. Cryptic splice sites (CSSs) in exons 5 and 11 are marked. Only the sequence within 125 nucleotides (nt) 
of exonic splice donor and acceptor consensus sequences has been analysed. Conserved ESEs are those sequences that were identical in human, 
primates, mouse cow, dog and opossum Brca1. Shared ESEs are those sequences for which ESEfinder predicted a binding site for the same 
arginine-serine rich protein (SR protein) to the same exon position but the motif sequence was not the same between species.
Table 2
Known BRCA1 sequence changes affecting potential ESEs in the BRCA1 open reading frame
Type Number examined Sequence changes 
resulting in loss of 
ESE
Sequence changes 
resulting in altered 
score of ESE
Sequence changes 
resulting in gain of 
ESE motif
Total sequence 
changes affecting 
putative ESEs (%)
M S 1 7 5711 3  ( 7 6 . 4 7 1 )
UV 387a 104 57 68 229 (59.173)
I F D / I 1 9 8321 3  ( 6 8 . 4 2 1 )
P1 2 3227  ( 5 8 . 3 3 3 )
NS 167 62 17 20 99 (59.281)
S50000  ( 0 . 0 0 0 % )
Total 607 182 86 93 361 (59.473)
aOne mutation listing in the Breast Cancer Information Core database as unclassified variant (UV) encodes a nonsense mutation. There are 386 
missense UVs. ESE, exonic splicing enhancer; IFD/I, in-frame deletion/insertion; MS, missense; NS, nonsense; P, polymorphism; S, change to 
splicing consensus sequence.Breast Cancer Research    Vol 7 No 6    Pettigrew et al.
R934
that applying the 125 nucleotide cutoff does indeed increase
the specificity of ESEfinder output.
To investigate whether evolutionary analysis was able to fur-
ther filter out false positives detected by ESEfinder, regions of
human and mouse intronic sequences were also analyzed
using ESEfinder. Again, the 125 nucleotide cutoff limit was
also used in this analysis. Shared and conserved motifs
between human and mouse introns were found to occur at a
frequency of 2.845 per 100 nucleotides of exonic sequence,
compared to 0.6 per 100 nucleotides of intronic DNA (P =
0.00005). This suggests that evolutionary conservation
together with the 125 nucleotide cutoff is likely to improve sig-
nificantly the specificity of the ESEfinder output.
Known BRCA1 sequence changes map to predicted 
exonic splice enhancers
The positions of ESEs predicted using the increased threshold
for the full wild-type BRCA1 coding sequence were compared
with the locations of BRCA1 sequence variants reported to
the BIC database (Table 2). A total of 607 reported sequence
variants in the BRCA1 ORF were examined, the majority (387)
being UVs. Nonsense mutations were included in the analysis
because such changes have previously been shown to induce
splicing defects [2]. Of the sequence variants analyzed, 268
are located within predicted ESEs. These variants either result
in loss of a potential ESE (n = 182), reduced score for an ESE
(n  = 48), or an increased score (n  = 38). A further 93
sequence variations analyzed were predicted to result in the
gain of one or more potential ESEs. A total of 59% (361/607)
of the sequence changes analyzed alter the ESEfinder predic-
tions for the complete BRCA1 ORF.
Table 3
BRCA1 sequence variants mapping to shared or conserved ESEs
Exon Predicted ESE ESE location in 
exon
Sequence 
change
Classa Number of 
times 
reported
Shared or 
conservedb
Affect on ESEc
2 SRp55 53 T172C M-UV 3 Conserved Decrease
3 SRp55 41 A243G M-UV 3 Conserved Increase
5 SRp40 72 A330G M 16 Conserved Increase
6 SF2/ASF 76 G411C M-UV 1 Shared Increase
8S C 3 5 4 7 A 6 0 9 C M - U V 1S h a r e d I n c r e a s e
12 SRp40 82 C4302T NS 26 Conserved Lose
13 SF2/ASF 1 C4305T NS 2 Shared Lose
16 SC35 113 4917del15 IFD 1 Shared Lose
17 SF2/ASF 68 C5173T M-UV 1 Shared Losed
18 SF2/ASF 4 G5199T NS 10 Shared Losed
18 SC35 22 G5215T M 1 Shared Lose
G5215A M 2 Decrease
20 SRp40 14 T5326C M-UV 6 Shared Decrease
A5328T NS 1 Decreased
G5331A M-UV 4 Decreased
G5332A M-UV 2 Losed
5332del3 IFD 2 Losed
20 SF2/ASF 15 A5328T NS 1 Shared Decreased
G5331A M-UV 4 Decreased
G5332A M-UV 2 Decreased
5332del3 IFD 2 Losed
20 SRp40 29 T5341G M-UV 3 Shared Lose
aClassification in Breast Cancer Information Core database: IFD, in-frame deletion; M, missense; M-UV, missense unclassified sequence variant; 
NS, nonsense. bExonic splicing enhancers (ESEs) shared or conserved between human, primates, mouse, cow, dog and opossum. cLose, loss of 
predicted ESE motif; increase, retain ESE motif with higher score; decrease, retain ESE motif with lower score. dAlter additional other ESE motifs.Available online http://breast-cancer-research.com/content/7/6/R929
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Of the BRCA1 sequence variants reported on BIC, 22 
colocalize with evolutionarily conserved exonic splice 
enhancers
Data from the ESE conservation analysis (with the 125 nucle-
otide cutoff) was then compared with the BRCA1 sequence
variants reported on the BIC database. This analysis identified
22 sequence variants colocalizing with shared/conserved
ESEs located within 125 nucleotides of exon junctions (Table
3), with a total of 14/23 (61%) of the predicted ESEs affected
by these sequence changes (Table 4). Importantly, these
sequence changes include the G5199T change in BRCA1
exon 18 that has previously been shown to affect ESE-medi-
ated splicing [2]. Interestingly, nine of the sequence changes
that localize to this subset of predicted ESEs are currently
classified as UVs.
Appying filters to the exonic splice enhancer prediction 
increases the colocalization with reported missense and 
insertion–deletion changes
To assess whether the prioritization process is predicting
BRCA1 ESEs that are more likely to be targeted by sequence
changes, we determined the percentage colocalization of
predicted ESEs with reported sequence changes in BIC
before and after increasing the ESEfinder threshold, consider-
ing the location relative to exon ends and taking into account
evolutionary sequence conservation (Table 4). Without any fil-
tering of ESE prediction, we found that 51.72% of predicted
ESE motifs colocalized with reported sequence variations.
After the full filtering process, in which the increased threshold
and 125 nucleotide limits were used along with full evolution-
ary analysis, we found that 60.87% of predicted ESEs colocal-
ized with reported sequence variations. Assuming that the
filtering process has enhanced the prediction of functional
ESEs in BRCA1, this suggests that at least a proportion of the
variants located within them may result in altered ESE function.
The effect of applying these filters on colocalization with the
different types of BRCA1 sequence variants was then deter-
mined. We hypothesized that if the filtering process was effec-
tive, then the colocalization with sequence changes most likely
to be disease associated would increase, whereas the colo-
calization with known polymorphisms would decrease. Con-
sistent with this hypothesis, the filtering process always
increased the percentage of ESEs colocalizing with possible
disease-associated changes (Table 4). This was especially
marked for missense changes, in which the increase was over
400% (P = 0.07), but was also observed for in-frame dele-
tions, with an increase of 53% (P = 0.4). In contrast, colocali-
zation with known polymorphisms decreased by 100% (P =
0.6).
In the analysis of colocalization with UVs, we first categorized
them according to their predicted affect on protein function.
One of the rationales for this stems from the previous report
that 'conservative' amino acid sequence changes in hMLH1
and hMSH2 genes colocalize with predicted ESEs, whereas
'radical' changes exhibit no association [39]. The majority of
UV sequence changes were predicted to be neutral (174/
254), which is consistent with the fact that a large proportion
of UVs are expected to be benign [31]. For deleterious UV
Table 4
Effect of filters on colocalization of predicted ESEs with reported sequence changes in the BRCA1 open reading frame
No filters Complete filtersa Percentage change from no filters 
to complete filters
Number of predicted ESEs 669 23 -
Percentage of predicted ESEs affected by sequence 
changes (% [n])
51.72% (346) 60.87% (14) +17%
Percentage of predicted ESEs affected by NSb sequence 
changes (% [n])
20.63% (138) 21.74% (3) +5%
Percentage of predicted ESEs affected by IFDb sequence 
changes (% [n])
8.52% (57) 13.04% (3) +53%
Percentage of predicted ESEs affected by Mb sequence 
changes (% [n])
1.64% (11) 8.70% (2) +430%
Percentage of predicted ESEs affected by UVb sequence 
changes predicted to be deleteriousc (% [n])
8.52% (57) 26.10% (6) +206%
Percent of predicted ESEs affected by UVb sequence 
changes predicted to be neutralc (% [n])
18.83% (126) 8.70% (2) -54%
Percent of predicted ESEs affected by Pb,d sequence 
changes (% [n])
4.19% (28) 0.00% (0) -100%
aIncreased threshold, location within 125 nucleotides of exon end and conserved in human, primate, mouse, cow, dog and opossum. 
bClassification in Breast Cancer Information Core (BIC) database: IFD, in-frame deletion; M, missense; M-UV, missense unclassified sequence 
variant; NS, nonsense. cDeleterious refers to amino acid sequence changes predicted most likely to affect protein structure and function. dP, 
polymorphisms include those reported in BIC and SNPper. ESE, exonic splicing enhancer.Breast Cancer Research    Vol 7 No 6    Pettigrew et al.
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sequence changes, an increase in colocalization was
observed (+206%), which was in accordance with observa-
tions for possible disease-associated changes. In contrast,
neutral UV sequence changes exhibited a decrease in colocal-
isation (-53.8%), similar to that observed for polymorphisms.
Rescue-ESE identifies a partially overlapping set of 
predicted exonic splice enhancers
An alternative ESE prediction program, namely 'Rescue-ESE',
has recently become available [10,33]. This program predicts
the presence of ESE motifs based on a list of 238 hexamer
motifs found to be significantly enriched in exonic sequence,
when compared with intronic sequence, and significantly
enriched in exons with weak splice signals compared with
exons with strong splice signals. In the Rescue-ESE program,
no account is taken of the known recognition sites of splicing
factors. A preliminary analysis of exons 2–10 of the BRCA1
gene using Rescue-ESE identified 116 potential ESEs, as
compared with 47 detected in the same region by ESEfinder
(Table 5). Strikingly, only 11 of the ESEs predicted by both
programs (23% of ESEs predicted by ESEfinder) were the
same. When evolutionary sequence conservation (with pri-
mates and mouse only for ESEfinder, and with mouse only for
Rescue-ESE) was taken into account, however, the proportion
of ESEfinder predicted ESEs that were also detected by Res-
cue-ESE increased to 45%. Together these findings support
the notion that evolutionary conservation analysis increases
the specificity of the current ESE prediction programs and
emphasizes the need for both improved algorithms and bio-
chemical validation of results. However, it should be noted that
Rescue-ESE can predict ESEs recognized by SR proteins
other than those used by ESEfinder.
Discussion
In this study we attempted to identify ESEs in BRCA1 and to
predict which are most likely to be functional. As one of the
ultimate purposes of the study was to determine the trans-act-
ing factors that are involved in splicing decisions of BRCA1,
our analysis principally focused on the ESE detection program
ESEfinder. Initial screens using this program generated a large
number of predicted ESEs in the BRCA1 gene. Evolutionary
conservation analysis reduced the number dramatically. The
observation that conserved ESEs are much more frequent in
exons than in introns (4.67:1 versus 1.10:1 for all ESEs) is
consistent with the fact that SR proteins primarily recognize
exonic sequences and suggests that evolutionary conserva-
tion analysis, together with applying the 125 nucleotide cutoff,
can reduce the number of false positives significantly. The low
frequency of conserved ESEs in introns may represent intronic
splicing enhancer sequences that bind to SR proteins or may
represent background noise in the prediction program.
Although intronic splicing enhancers are best known for their
association with the spliceosome [40,41], it is also known that
SR proteins can bind to intronic splicing elements [42].
The increased threshold used in the ESEfinder analysis was
designed to reduce the number of potential false-positive
results. Increased thresholds have been used in bioinformatics
analysis previously with other cancer-related genes, including
hMSH1  and  hMLH2  [39], and TP53  [23]. In their earlier
report, Gorlov and coworkers [39] employed an increased
threshold of 3.0 for SF2/ASF in preference to the recom-
mended 1.956. In their more recent report [23], the threshold
score used for analysis of TP53 for SF2/ASF was 2.0. Liu and
coworkers [2] previously identified and biochemically analyzed
an ESE motif recognized by SF2/ASF in exon 18 of BRCA1,
with an ESEfinder score of 2.143. Therefore, had the
increased threshold score of 3.0 been used for SF2/ASF in
this study, then at least one confirmed ESE would have been
missed. The creators of ESEfinder also emphasize that there
is no strict quantitative correlation between numerical scores
and ESE activity [11], particularly because ESEs are depend-
ent on other important variables such as splice site strength,
local sequence context and the presence of other splicing cis-
elements.
Table 5
Comparison of ESEfinder and Rescue-ESE programs for identification of potential ESEs in exons 2–10 of the BRCA1 gene
ESEs predicted by 
ESEfinder
ESEs predicted by 
Rescue-ESE
ESEs predicted by both 
programs
Proportion of ESEfinder 
predicted ESEs also 
detected by Rescue-ESE
BRCA1 exons 2–10 (total) 47 116 11 23%
BRCA1 exons 2–10 
(conserved or shared 
ESEs between human 
and mouse)
20 69 9 45%
BRCA1 exons 2–10 
(conserved or shared 
ESEs between human 
and mouse affected by 
breast cancer associated 
sequence changes)
16 16 3 19%Available online http://breast-cancer-research.com/content/7/6/R929
R937
ESEs are often found grouped in areas within exons [43].
Therefore as expected, many predicted ESEs overlapped par-
tially or entirely with other predicted ESEs for identical or dif-
ferent SR proteins. Consequently, the amount of BRCA1
coding sequence covered by the 464 predicted ESEs is only
2388 nucleotides, which is 42% of the ORF. This is lower than
the 57% of sequence covered by predicted ESEs for another
tumor suppressor gene, namely TP53 [23]. Interestingly, only
two natural alternatively spliced isoforms of TP53 have been
found [44,45], compared with the four predominant isoforms
of BRCA1 (for review, see Orban and Olah [18]).
BRCA1 produces four predominant splicing isoforms – the
full length, ∆9–10, ∆9–10,11q and ∆11q isoforms – at varying
levels in a range of cell and tissue types [46,47] (for review,
see Orban and Olah [18]). Two of these predominant variants
(∆11q and ∆9–10,11q) employ a cryptic splice site located
118 basepairs into exon 11, and when used lead to a deletion
of over 3 kilobases of the exon. We excluded the majority of
exon 11 by limiting the analysis, looking at only the first 125
and final 125 nucleotides of the exon. No conserved or shared
ESEs were located in these regions of exon 11, but this anal-
ysis may have missed potentially active sequences. Given that
exon 11 is unusually large for an exon, it is possible that splic-
ing regulatory elements are active throughout the exon to
ensure accurate splicing. Fewer ESEs in proximity to the splice
site required for full length exon 11 may contribute to a less
efficient recognition of the splice site by the spliceosome, and
as a consequence the spliceosome may have a higher affinity
for the upstream cryptic splice site. Currently, only the ∆11
Brca1  splice variant has been confirmed to be present in
mouse [48,49], but no comprehensive search results have
been reported for alternatively spliced Brca1 transcripts. Inter-
estingly, during cloning of the bovine Brca1 cDNA, the alter-
natively spliced transcripts ∆11 and ∆11b were detected in
spleen RNA [50].
The association of BRCA1 sequence variants with predicted
ESE motifs before incorporation of evolutionary data varies
between exons. Exon 5 contains a high percentage of
sequence variants located in predicted ESEs, and has previ-
ously been shown to be alternatively spliced [3,51-53]. Some
of these alternatively spliced transcripts arise due to sequence
mutations, whereas others appear to be expressed normally.
The high number of predicted ESEs associated with sequence
variants in exon 5 may indicate that these ESEs play functional
roles in BRCA1 splicing processes.
Comparing prioritized predicted ESEs with known sequence
variants in BRCA1 highlights 14 reported sequence changes
that are predicted to affect ESEs (Table 3). Importantly, the
G1599T mutation that has previously been shown to affect
ESE-mediated splicing of BRCA1 [2] was included in this
group. Nine (50%) of the sequence changes affecting con-
served or shared predicted ESEs are currently designated as
UVs. Although genetic and cellular studies are currently ongo-
ing to classify such variants [54-56], the fact that they map to
these conserved ESEs suggests that RNA splicing analyses
(e.g. Tesoriero and coworkers [9]) should be included in the
list of assays used to investigate the consequences of these
sequence changes.
Conclusion
This in silico study has prioritized a select group of predicted
ESEs for functional analysis. These ESEs may be critical in
regulating the alternative splicing patterns of BRCA1, and dis-
ruption of alternative splicing may have important implications
for breast tumorigenesis. We show that a combination of
threshold score, position relative to exon:intron boundaries
and evolutionary conservation may significantly improve the
specificity of the ESEfinder output (Table 4, Fig. 2). The study
also classified a subset of BRCA1 UVs as potentially affecting
BRCA1 splicing via disruption of predicted ESEs. It is also
possible that there remains a number of mutations in the BIC
database that have been classified incorrectly, such as
G5199T, which is currently listed as a nonsense mutation,
although it has been shown to alter BRCA1 splicing [2]. The
data generated in the present study may be considered useful
but not definitive for the assignment of pathogenicity of
sequence variants. Indeed, comparing ESEfinder with Res-
cue-ESE (Table 5) highlights the need for additional comple-
Figure 2
Prioritizing ESEs in the coding region of BRCA1 Prioritizing ESEs in the coding region of BRCA1. Shown is a flow dia-
gram of the process of prioritizing exonic splicing enhancers (ESEs) in 
the BRCA1 open reading frame for biochemical analysis. Numbers indi-
cate predicted ESEs following each stage.Breast Cancer Research    Vol 7 No 6    Pettigrew et al.
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mentary analyses such as evolutionary conservation.
Ultimately, however, functional analysis of these prioritized
predicted ESEs and corresponding sequence changes will be
essential to validate the in silico approach used in this and
other studies.
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